Tempest Therapeutics Inc.

09/20/2021 | Press release | Distributed by Public on 09/20/2021 06:07

Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche